Hepatoblastoma (HB) is the most common malignant tumor of the liver in children
in countries where hepatitis B is not endemic, and this has also been the case in Taiwan since nationwide hepatitis B vaccinations were implemented in 1984. The outcome of HB has become much better in the past two decades because of improved imaging modalities, adjuvant and neoadjuvant chemotherapy, and technical improvements in liver resection and liver transplantation. In this mini-review, the current strategy of HB treatment as reported in the literature will be described.